What is the Org number of Legemiddelservice AS?

Legemiddelservice AS is registered with Brønnøysundsregistrene under Org 982752744.

What is the revenue of Legemiddelservice AS?

Legemiddelservice AS reported revenue of 8,7 mill. kr in 2025.

Legemiddelservice AS employs 1 people as of the latest annual report.

Leif Rune Skymoen is the CEO of Legemiddelservice AS, in role since 2023.

Cathrine Thomassen chairs the board of Legemiddelservice AS, in role since 2024.

Legemiddelservice AS's registered address is Essendrops Gate 3, 0368 Oslo.

ASActive

Org 982752744Essendrops Gate 3, 0368 OsloPublishing of journals and periodicals· NACE 5813Est. 2001 · 25 years old1 employees

Actively employed in the business

Name	Role	Member since
Current (1)
LR Leif Rune Skymoen Chief Executive Officer	Chief Executive Officer	2023

Former (2)


KØ Kjetil Østreng Evensen Chief Executive Officer	Chief Executive Officer	2022 – 2023
KB Karita Bekkemellem Chief Executive Officer	Chief Executive Officer	2009 – 2022

Non-executive oversight

Name	Role	Member since
Current (9)
GB Guro Bjøntegaard Board of Directors	Board of Directors	2023
NT Nina Therese Hovland Board of Directors	Board of Directors	2026
VB Veronika Barrabès Board of Directors	Board of Directors	2023
EJ Emma Jayne Setter Board of Directors	Board of Directors	2026
SM Sebastian Marcus Heckerodt Board of Directors	Board of Directors	2025
AM Anne Merete Sveaass Board of Directors	Board of Directors	2024
ML Morten Lofthus Tangnes Board of Directors	Board of Directors	2023
CT Cathrine Thomassen Chairman	Chairman	2024
KN Kirsti Nyhus Board of Directors	Board of Directors	2023

Former (10)


MK Mario Klesse Board of Directors	Board of Directors	2022 – 2023
DJ Duarte Joao Lourinho Marchand Board of Directors	Board of Directors	2022 – 2024
LR Leif Rune Skymoen

As of last annual report

Shareholder	Type	Ownership	Votes	Since
Legemiddelindustrien	Company	100%	100%	2025

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.